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Abstract
The TRIM family of proteins is distinguished by its tripartite motif (TRIM). Typically, TRIM proteins contain a RING finger
domain, one or two B-box domains, a coiled-coil domain and the more variable C-terminal domains. TRIM16 does not have
a RING domain but does harbour two B-box domains. Here we showed that TRIM16 homodimerized through its coiled-coil
domain and heterodimerized with other TRIM family members; TRIM24, Promyelocytic leukaemia (PML) protein and Midline-
1 (MID1). Although, TRIM16 has no classic RING domain, three-dimensional modelling of TRIM16 suggested that its B-box
domains adopts RING-like folds leading to the hypothesis that TRIM16 acts as an ubiquitin ligase. Consistent with this
hypothesis, we demonstrated that TRIM16, devoid of a classical RING domain had auto-polyubiquitination activity and acted
as an E3 ubiquitin ligase in vivo and in vitro assays. Thus via its unique structure, TRIM16 possesses both heterodimerization
function with other TRIM proteins and also has E3 ubiquitin ligase activity.
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Introduction
The tripartite motif (TRIM)/Ring finger, B box, coiled-coil
(RBCC) family of proteins are defined by the presence of the
tripartite motif. The TRIM protein family is composed of more
than 70 highly conserved proteins which have been implicated in
a diverse range of biological processes including development, cell
growth, differentiation, innate immune functions and cancer [1,2].
One poorly characterized member of this family is TRIM16.
TRIM16 or estrogen-responsive B box protein (EBBP) is a positive
transcriptional regulator of the retinoic acid receptor b2 (RARb2)
gene [3,4]. TRIM16 overexpression also enhances retinoid-
induced differentiation, reduces neuroblastoma cell growth,
migration, and significantly reduces tumorigenicity in vivo [5].
Typically, TRIM proteins contain a Really Interesting New
Gene (RING) finger domain, one or two B-box domains, a coiled-
coil domain and the more variable C-terminal domains. The
RING and B-box domains are both cysteine-rich and bind zinc
atoms, indicating possible interactions with proteins, DNA and
RNA. The RING domain has E3 ubiquitin-ligase potential and
can transfer ubiquitin to RING proteins as well as heterologous
substrates [1,2]. However, little is known about the function of B-
box domains, although they occur widely in nature. Recently, the
first solved structure of a B-box domain displays a structure similar
to a RING domain, suggesting these domains evolved from
a common ancestor [6,7]. TRIM16 does not have a RING
domain but does harbour two B-box domains, leading to the
hypotheses that TRIM16 has RING-like domains and functions as
an ubiquitin ligase. TRIM16’s C-terminus contains an RFP-like or
B30.2/SPRY (B30.2) domain.
Several members of the TRIM protein family are known to
homodimerize and heterodomerize with other TRIMs, and the
coiled-coil domain is generally required for these functional
associations [8,9]. In this study, we show that TRIM16 can
homodimerize through its coiled-coil domain but also bind to
other TRIM proteins; Midline-1 (MID-1/TRIM18), Promyelocy-
tic leukemia protein (PML/TRIM19) and TRIM24 (TIF-1a).
Additionally, our molecular modelling of TRIM16’s B-boxes
suggests zinc binding capability and we present evidence that B-
box domains have ubiquitination capability, leading to the
suggestion that other B-box-containing proteins may perform
a similar function.
Results and Discussion
TRIM16 Homodimerizes via Its Coiled-Coil Domain
In the large and evolutionary conserved TRIM family, specific
domains tend to operate as functional units. Many TRIM proteins
homodimerize via their coiled-coil domains [2,8,9]. To further
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37470investigate the function of TRIM16, we tested whether TRIM16 is
able to homodimerize. Two differently tagged TRIM16 expression
vectors and 5 different deletion mutants of TRIM16 were used
(Figure 1A); TRIM16-GFP and TRIM16-myc-his with both tags
being fused separately to the C-terminus of the TRIM16 protein.
The full-length TRIM16 and 5 deletion constructs were used to
probe for the role of various domains in protein function
(Figure 1A). HEK293 cells were co-transfected either empty
vector pCMV6-AC-GFP and TRIM16-GFP or empty vector (EV)
pCDNA-myc-His and TRIM16-myc-His. Immunoprecipitation of
the myc-tag strongly indicated that TRIM16-GFP and TRIM16-
myc-His were homodimerizing (Figure 1B). We confirmed these
results by using the anti-GFP antibody (Ab) for immunoprecipi-
tation, and investigating whether GFP-tagged deletion mutants of
TRIM16 were able to retain homodimerization with the
TRIM16-myc-His. GFP fusion mutants bearing coiled-coil
Figure 1. TRIM16 homodimerizes through its coiled-coil domain. (A) TRIM16-GFP domain deletion plasmids. (B) Co-transfection of TRIM16-
GFP and TRIM16-myc-His in HEK293 cells and subsequent immunoprecipitation by anti-myc antibody (Ab) and Western blot with anti-GFP antibody.
Whole cell extract (WCE) used as total input. (C) TRIM16 homodimerizes through its coiled-coil domain. GFP deletion mutants were co-transfected
with the TRIM16-myc-His vector. Anti-GFP antibody was used to pull down proteins binding the GFP tagged proteins and the TRIM16-myc-His was
used to detect self-association via its different tag (right panel). Transfection efficiency was confirmed (left panel). TRIM16-GFP mutants were
efficiently pulled down (middle panel). * non-specific bands, # refer to text.
doi:10.1371/journal.pone.0037470.g001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37470Figure 2. TRIM16 can heterodimerize with MID1, TRIM24 and PML. (A) Schematic structures of TRIM proteins used in heterodimerization
studies. (B) TRIM16 binds MID1. Co-transfection of MID1-GFP and TRIM16-myc-His in HEK293 cells and subsequent immunoprecipitation by anti-myc
antibody and Western blot with anti-GFP antibody. (C) MID1 was pulled down via its GFP antibody and a Western blot was performed to detect
TRIM16-myc-His in the immunoprecipitated protein complex. (D) Whole cell lysates (WCL) of HEK293 cells transfected with empty vector (EV) or
TRIM16-GFP were immunopreciptated with anti-GFP antibody. An anti-PML antibody was used to detect PML as a binding partner of TRIM16. (E)
Lysates containing both TRIM16-GFP and TRIM24-His proteins were immunopreciptated with anti-GFP antibody. Anti-His antibody was used to detect
the presence of TRIM24 in the TRIM16-associated complex.
doi:10.1371/journal.pone.0037470.g002
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TRIM16-myc-His protein, indicating this region is required for
TRIM16 homodimerization (Figure 1C and 1A). However a weak
band (Lane 6 in Figure 1C) indicates that B-boxes are able to form
some homodimers to a lesser extent.
TRIM16 Heterodimerizes with MID1, TRIM24 and PML
TRIM proteins have been shown to interact with other TRIM
family members. For example, TRIM24 is known to bind PML
[10] and RET finger protein (RFP/TRIM27) through the B-box
and coiled-coil domains [11]. Therefore it was important to
establish whether TRIM16 may also form hetero-complexes.
PML, TRIM24 and MID1 (Figure 2A) have E3-ligase ability
through their RING domain and generally homo/heterodimerize
through their coiled-coil domains [2,8,9]. To determine whether
MID1 could interact with TRIM16, we performed co-transfection
of MID1-GFP and TRIM16-myc-His in HEK293 cells and
subsequent performed immunoprecipitation by anti-myc antibody
and western blot with anti-GFP antibody (Figure 2B). Co-
immunoprecipitation confirmed that TRIM16 and MID1 formed
a complex in HEK293 cells (Figure 2B). The specificity of this
interaction was validated by MID1 immunoprecipitation with an
anti-GFP tag antibody and Western blot analyzed by myc-tag
antibody, probing for TRIM16-myc-His (Figure 2C). The in-
teraction with MID1 suggested that TRIM16 may have a function
in the cytoskeleton, as MID1 associates with the microtubules and
the cytoskeleton [12]. Interestingly, TRIM16 has been previously
shown to bind the cytoskeletal protein; vimentin [5], further
suggesting TRIM16 may has a role in the cytoskeleton function.
Other TRIM proteins, TRIM24 and PML also displayed
binding with TRIM16 (Figure 2D and 2E). TRIM16-GFP was
immunoprecipitated via its GFP tag, and the resulting associating
proteins were subjected to western blot and probed for PML (anti-
PML antibody) or TRIM24-His (anti-His antibody). In addition to
the interaction observed with MID1, the interactions with
TRIM24 and PML proteins demonstrate that TRIM16 is able
to heterodimerise with at least three different classes of TRIM
proteins.
TRIM16 is known to bind the promoter region of the RARb
gene [3]. Interestingly, TRIM24, also a transcription factor, has
been shown to act in a complex with PML and the RARa and
RXR receptors, which are known to bind the same promoter
region sequence of RARb as TRIM16 [10,13]. PML is a tumour
suppressor which has a significant role in the cell-cycle,
differentiation and apoptosis. PML is required for the formation
of large protein complexes called PML-bodies which are believed
to have a role in transcription. PML and TRIM24 do not possess
a B30.2 domain which suggests TRIM16’s heterodimerization is
through the other domains on these proteins.
TRIM16’s B-Boxes Possess RING-Like Folds
The solution structure of MID1’s B-boxes reveals they adopt
RING-like folds with a modelled capacity for zinc-binding and
possibly ubiquitination activity [7,14]. We hypothesized that the
B-boxes of TRIM16 also have RING-like folds. An amino acid
sequence alignment of the human MID1 sequence with TRIM16
from various species was performed (Sim, ExPASy, CA). There
was 46% sequence identity between the human B-box1 sequences
of the two proteins (Figure 3A). TRIM16 shares the zinc binding
consensus sequence to MID1 with the exception of the 6
th cysteine
residue of the MID1 B-box1’s consensus sequence being
substituted with a histidine residue in TRIM16. Other TRIMs
(eg.TRIM29 (ataxia-telangiectasia group D complementing gene)
and TRIM25 (The estrogen-responsive gene/EFP) also share this
particular substitution [6]. An unbiased blast search of the NCBI
database with TRIM16’s B-box1 sequence yields significant
sequence identity with human TRIM16, TRIM29, TRIM25,
MID1, RFP and MID2 (only TRIMs resulted, in order of
significance all with E-values ,0.009, and scores above 37.7).
Analysis of TRIM16’s B-box2 sequences yielded similar results to
B-Box1 (Figure 3B), although with a lower human sequence
identity (28%) to MID1 (Sim, ExPASy, CA). When comparing the
full-length of the sequence, TRIM16 shares low sequence identity
with other TRIMs such as TRIM29, TRIM25, RFP, MID1 and
MID2, except in the B-box1 region where the high homology
amongst these TRIMs suggests a subgroup of TRIMs having
a specific zinc-binding role in homeostasis.
To gain greater insight into the structure of TRIM16, the amino
acid sequence for human TRIM16 was threaded onto the top ten
protein structure templates as predicted by the HHpred program
(http://toolkit.tuebingen.mpg.de/). A homology model of the
whole of TRIM16 was then constructed using MODELLER [15].
The homology model predicted a structured region for the B-Box
domains; (Cys77 to His117 and Cys131 to His160) and the B30.2
domain (Pro379 to Leu536). The coiled-coil region could not be
modelled, as no suitable templates existed. The B-box region
quality of the model was confirmed by the PROCHECK program
[16] which showed .97% of residues had backbone geometry
falling in the favourable regions of the Ramachandran plot.
Furthermore, superimposition of the B-box domains of TRIM16
onto the NMR solution structures of MID1 B1B2, not in the
structure templates used for homology modeling, gave a very close
overlay with an average a-carbon root-mean-square deviation of
0.4 A ˚ (Figure 3C). TRIM16’s B-Boxes form an unusual ‘‘cross-
brace’’ arrangement or ‘‘Intermolecular Ring Heterodimers’’
capable of zinc binding [14,17,18]. For Zn1, the coordinating
residues are Cys77, Cys80 and His104; for Zn2, the residues are
Cys86, Cys96, His 108 and His 117; for Zn3 they are Cys131,
His134, Cys150 and Cys153; and for Zn4 the residues are Cys142,
His157 and His160 (Figure 3D). The RING domain and B-box
domains may share an ancestral motif [7,14]. TRIM16 is one of
the oldest TRIMs [19], yet is the only functionally studied TRIM
with a B1-B2-CC-B30.2 motif, indicating the evolution of a RING-
less TRIM is an ancient and biologically required phenomenon.
TRIM16 Auto-Ubiquitinates via Its B-Boxes
Several TRIM proteins with RING domains have been
implicated in the proteolysis, acting as E3 ubiquitin ligases.
However, B-boxes are required for the E3 ligase ability of PML
and its ability to transfer the small ubiqutin-like modifier (SUMO)
from Ubc9 to p53 [20]. Similarly, MID1’s B-boxes enhance the
E3 activity of its RING domain [21].
Protein ubiquitination occurs in a series of reactions in which
a molecule of ubiquitin is transferred from the activating enzyme
(E1), to a conjugating enzyme (E2), and, with the involvement of
an E3 ligase, to a substrate or to the E3 ligase itself. Common
features of E3 ligases are their ability to auto-ubiquitinate and self-
degrade. TRIM16 is itself an unstable protein, degraded by
proteasome mediated degradation. In various cell lines, TRIM16
protein quantity was increased after the proteasome inhibitor
MG132 treatment (Figure 4A). Furthermore, TRIM16 has a short
protein half-life around 4 hours measured by cycloheximide-based
protein chase experiments in both SH-SY5Y and HEK293 cells
(Figure 4B).
This result, together with the fact that TRIM16’s B boxes can
adopt a RING-like structure moved us to investigate whether
TRIM16 exhibits E3 ubiquitin ligase activity catalyzing auto-
ubiquitination. TRIM16 E3 ligase activity was first examined by in
TRIM16 Has Ubiquitin Ligase Activity
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37470Figure 3. Amino acid sequence comparison of TRIM16 and MID1 and modeling of TRIM16 B-boxes. The conserved residues in the zinc
binding regions are in bold underlined type and are; cysteine; C, histidine; H, alanine; A aspartic acid; D. (A) TRIM16 and MID1 share the zinc binding
consensus sequence for B-box1. (B) TRIM16 and MID1 share the Zinc binding consensus sequence for B-box2. (C/D) Modeling of B-boxes reveals zinc
binding capability. Superimposition of the alpha-carbon backbone of the B-boxes from the MDM1 NMR structure (purple) and the homology model
of TRIM16 (blue-grey). These two structures overlay with an average root-mean-square deviation of 0.4 A ˚.
doi:10.1371/journal.pone.0037470.g003
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deletion mutants (Figure 1A) and HA-tagged ubiquitin (Ub) were
expressed in HEK293 cells; The cells were treated with MG132
four hours prior harvesting to preserve the polyubiquitin chains.
GFP-tagged proteins were immunoprecipitated and the presence
of polyubiquitinated TRIM16 was detected by Western blot. Only
full-length TRIM16 has a high-molecular-weight smear, repre-
senting polyubiquitinated TRIM16 as detected by anti-GFP and
anti-HA antibodies (Figure 5A).
TRIM16 E3 ubiquitin ligase activity was further examined by in
vitro reaction.TRIM16-myc-Hiswasincubated in vitro togetherwith
recombinanthumanE1,apanelofE2enzymes,HA-taggedUband
ATP. TRIM16 showed auto-polyubiquitination activity with
a specific family of E2 enzymes, UbcH5 (UbcH5a, UbcH5b,
UbcH5c) (Figure 5B). Other E2 enzymes tested produced no auto-
polyubiquitination. To test whether B-Boxes of TRIM16 are
required for auto-polyubiquitination, myc-His tagged
TRIM16 and TRIM16 domain deletion mutants were
incubated as above with E1, UbcH5b or catalytically inactive
UbcH5b (C85A) enzymes. Extensive high molecular weight smears
representing polyubiquitinated TRIM16, as detected by Western
blot with anti-myc antibodies, is observed in the presence of
catalytically active UbcH5b and wild-type TRIM16. In reaction
where wild-type UbcH5b was substituted with a catalytically
inactive variant UbcH5b (C85A), this auto-polyubiquitination was
abolished (Figure 5C). To investigate whether recombinant
TRIM16 synthesized using cell free system is able to auto-
ubiquitinate in vitro, we have performed an in vitro ubiquitination
assay.RecombinantTRIM16purifiedfromwheatgermextractwas
incubated in vitro together with recombinant human E1, UbcH5b,
HA-tagged Ub and ATP; reaction was supplemented with zinc
chloride (Zn) as described in Takahashi H et al, 2009 [22]. High-
molecular-weight TRIM16 was detected when Zn and ATP were
present in the assay (Figure 5D, lane 1).
The RING domain is typically known for its E3 ubiquitin ligase
potential. Here we have demonstrated for the first time that
a protein devoid of a classical RING domain can bind ubiquitin
and auto-ubiquitinate via its B-boxes and function as an E3 ligase.
In this report, we provide a first clue as to the function of the
TRIM16 protein which is devoid of a classic RING domain. A
surprising result of our study is that the B-boxes of TRIM16
exhibit an E3 ligase activity. We have also found that TRIM16
can homo and hetero-dimerize, a common feature found in other
TRIMs. Therefore, in addition to its role as an E3 ligase we
cannot exclude the possibility that TRIM16 may also control the
stability of other TRIM proteins or that TRIM16 may function in
a multi-subunit complex with other TRIMs enhancing their E3
ligase activity.
The proteasome degradation pathway remains one of the most
powerful regulatory systems in cells of normal and malignant
phenotypes. In recent years, an important function of TRIM
proteins in mediating the transfer of ubiquitin to substrates as well
as to themselves (auto-ubiquitination) have been shown to be
involved in a number of critical processes in cell signalling, survival
pathways and differentiation. Therefore, the interactions of the
TRIM proteins have far reaching implications in all aspects of
cells. Due to the scope of TRIM16 protein binding and structure
studies as outlined here, our work suggest that TRIM16 is a useful
biological model for the study of TRIM protein and ubiquitin
interactions in the absence of the RING domain. Although
TRIM16 lacks a RING domain, it nonetheless possesses important
ubiquitination and heterodimerization functions, the implication
of these functions in normal and cancer cells will need to be further
elucidated.
Materials and Methods
Cell Culture and Conditions
BE2C, SHEP and SH-SY5Y cell lines were gifted by Dr. J.
Biedler (Memorial Sloan-Kettering Cancer Center, New York).
The human embryonic kidney 293 cells (HEK 293) were
purchased from the American Type Culture Collection. All cells
Figure 4. TRIM16 is an unstable protein regulated by the ubiquitin-proteasome system. (A) In vivo degradation assay was performed with
cells being incubated with and without 30 mM MG132 for 4 hours. Lysates were subjected to Western blot analysis of endogenous TRIM16 antibody.
(B) The liable nature of TRIM16 was further evaluated by inhibition of protein synthesis using 100 mg/ml cycloheximide. At the specified time points
the cells were harvested and the protein were extracted for analysis by Western blots.
doi:10.1371/journal.pone.0037470.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37470Figure 5. B-boxes are required for TRIM16’s E3 ligase activity. (A) TRIM16 in vivo polyubiquitination assay. In HEK293 cells, HA-Ub was co-
transfected with various TRIM16-GFP domain deletion expression plasmids. The protein lysate was subjected to immunoprecipitation by GFP
antibody, and subjected to Western blot and probed with anti-HA antibody for Ub (right panel) and anti-GFP antibody for TRIM16 (left and middle
panel). Two exposure times are shown. GFP antibodies detect both un-ubiquitinated and polyubiquitinated forms of TRIM16. Polyubiquitinated
smear is present in the sample transfected with wild-type TRIM16 and shown by anti-GFP and anti-HA antibodies. (B) In vitro ubiquitination assay with
myc-His tagged TRIM16 together with a panel of E2 enzymes, showing activity with the UbcH5 family. (C) In vitro ubiquitination assay with full-length
TRIM16, TRIM16 domain deletion mutants or empty vector showing extensive polyubiquitination with full-length TRIM16 as detected by Western blot
with anti-myc antibodies. Numbers indicate protein size in kDa. (D) Recombinant TRIM16 (Abnova) was evaluated for E3 activity in the presence of
TRIM16 Has Ubiquitin Ligase Activity
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medium supplemented with L-glutamine and 10% fetal calf
serum. For TRIM16 stability experiments, 30 mM of MG132
(Biomol, USA) was used in complete culture medium for 4 hours
and 100 mg/ml cycloheximide (Biomol) for incubation of specified
times.
Transient Transfection
Transfections were carried out for 8 hours using Lipofectamine
2000 (Invitrogen, CA) according to the manufacturer’s instruc-
tions. Cells were harvested at 36 hours post-transfection or 28
hours for ubiquitination assays.
Expression Vectors
The TRIM16 full-length cDNA was subcloned into the
pcDNA3.1(-)/myc.His vector at the EcoRI multi-cloning site.
The TRIM16-GFP deletion mutants were produced by OriGene
(Rockville, MD, USA). The deletion mutants were synthesized by
PCR of full-length TRIM16 cDNA (NM_006470.3). The final
mutants were in the pCMV6-AC-GFP vector. In Figure 1A, the
mutant products correspond to the following amino acid (AA)
sequences; AA 1–564 (full-length), AA 161–564 (M1), AA 290–564
(M2), AA 1–372 (M3), AA 1-165 (M4) and AA 1-294 (M5) [3,5].
Western Blotting and Immunoprecipitation (IP)
Anti-TRIM16 (Bethyl Laboratories, TX), anti-TurboGFP
(Evrogen, Moscow), anti-Actin (Sigma, Sydney), and anti-myc
tag Abs (Cell Signalling Technology, MA) were used in Western
blots. Anti-His tag (Cell signaling, USA), anti-HA tag (Cell
signaling, USA) and anti-PML (Santa Cruz Biotechnology, USA)
antibodies were used in IP assays. For IP studies, cells were lysed in
NP-40 buffer with 150 mM NaCl and protease inhibitors (Roche,
Sydney). Lysates containing 0.5 mg of protein were immunopre-
cipiated with 1 mL of specified Abs.
In Vivo Ubiquitination Assay
Cells were transfected with GFP/myc tagged TRIM16/mutant
and HA-Ub expression plasmid for 24 hours following 4 hours
incubation with the proteasome inhibitor MG132 (Biomol, USA)
to preserve the polyubiquitin chain and then lysed under
denaturing conditions. 2 mg of protein was immunoprecipiated
with specified antibodies. After immunoprecipitation, the samples
were washed and resolved by SDS-PAGE and analysed by western
blot using anti-HA antibody.
In Vitro Ubiquitination Assay
TRIM16-myc-His, expressed in HEK293 cells was precipitated
using myc-tag Ab and GammaBind G sepharose beads (GE
Healthcare, USA), beads were extensively washed and incubated
for 90 minutes at 32uCi nIn Vitro Ubiquitination Buffer (25 mM
Tris-HCl pH 7.6, 5 mM MgCl2, 100 mM NaCl) containing
100 ng of E1, 150 ng of E2 enzymes (Boston Biochem, MA),
5 mg of HA-Ub (Boston Biochem, MA), 2 mM ATP (Sigma
Aldrich) and 2 mM DTT (Sigma Aldrich). After incubation, beads
were extensively washed and subjected to Western blotting. In vitro
ubiquitination assay containing 500 ng of recombinant TRIM16
(Abnova) and 10 mM ZnCl2 was performed as described above.
Computational Modeling
The amino acid sequence of the whole human TRIM16 was
threaded onto the top 10 protein structure templates predicted
using HHpred on the Max Plank Bioinformatics Server (http://
toolkit.tuebingen.mpg.de/) and a homology model was con-
structed using MODELLER (http://salilab.org/modeller/) [10].
The solution structures of MID1 B1B2 boxes were downloaded
from the Protein Data Bank (PDB) [11]. The top 10, of the 20
solution structures of MID1 were aligned via its a-carbons with
the B-box model of TRIM16 in Pymol [12]. Zinc ions in
TRIM16 were positioned in the same location as found in MID1
using Sybyl-X1.1. This model was then minimized under the
MMFFs force field in Sybyl-X1.1 until energy convergence was
reached (58043 iterations).
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